ライフサイエンスコーパス: platelet number

1 ne (Mpl), is the major cytokine regulator of platelet number.

2 ocytopoiesis, resulting in normal peripheral platelet number.

3 namic responses, or changes in leukocyte and platelet number.

4 cytosis and megakaryocytic atypia but normal platelet number.

5 s in the marrow and consequently circulating platelet numbers.

6 , decreased NF-E2 expression, and normalized platelet numbers.

7 Ca(2+) increases and influences circulating platelet numbers.

8 ytes led to clinically relevant increases in platelet numbers.

9 )/Fli1(DeltaCTA) homozygous mice has reduced platelet numbers.

10 to achieve clinically relevant increases in platelet numbers.

11 d neutropenia, but no changes in circulating platelet numbers.

12 n of the S1P(1) receptor altered circulating platelet numbers acutely, suggesting a potential therape

13 atelets/nL, but it is not entirely clear how platelet numbers affect hemostasis and occurrence of thr

14 Platelet numbers also increase during ex vivo storage.

15 ced a marked and dose-dependent elevation in platelet number and a moderate increase in mean platelet

16 te ploidy, and moderate increases in resting platelet number and platelet recovery following a thromb

17 Platelet number and volume are independent risk factors

18 Homozygotes show a 20-fold decrease in platelet numbers and a 3-fold increase in platelet size

19 ditary platelet disorders typified by normal platelet numbers and a prolonged bleeding time.

20 Concurrent with a decrease in platelet numbers and an increase in circulating monocyte

21 ve decreased peripheral blood lymphocyte and platelet numbers and developed chronic colitis.

22 therapeutic targets in the normalization of platelet numbers and function in diabetes.

23 g often reveals a range of changes affecting platelet numbers and function, procoagulant or anticoagu

24 aracterized by thrombocytopenia with reduced platelet numbers and functions, and a tendency to develo

25 -/-) mice show intact proplatelet formation, platelet numbers and shape, and marginal MT bands; thus,

26 new therapeutic strategies to modulate both platelet numbers and their thrombogenicity.

27 tations, such as thrombocytopenia (i.e., low platelet numbers) and anemia.

28 coagulation, including fibrinogen levels and platelet numbers, and cellular constituents of blood, su

29 ignificant decrease of CRP levels, increased platelet numbers, and clinically decreased bleeding seve

30 erythroblast proliferation, whereas reduced platelet numbers are associated with impaired platelet s

31 At the same time that platelet numbers are increased, the mean platelet volume

32 quency, especially due to the measurement of platelet number as part of routine blood testing.

33 The mutant mice have markedly reduced platelet numbers, associated with deregulated megakaryoc

34 yte potential, c-myb-null fetuses had normal platelet numbers at E12.5 but became thrombocytopenic by

35 lls or white blood cell differential counts, platelet number, bleeding time, hemoglobin, hematocrit,

36 equired for the control of megakaryocyte and platelet number but not for their maturation.

37 micrograms/kg/d) had accelerated recovery of platelet numbers compared with BMT mice treated with car

38 Thereafter, platelet number declined and returned to baseline by day

39 Human platelet numbers decreased from 102 +/- 33 at beginning

40 n, we sought to determine whether decline in platelet number during acute infection results from decr

41 t activity may be of greater importance than platelet number for clot integrity.

42 prothombin time) remained normal until after platelet numbers had declined significantly, arguing aga

43 e by day 2-4 after infection) in circulating platelet number in both C3H/HeN and C57BL/6J mice during

44 een any of the groups, with the exception of platelet number in the control group (P = 0.004).

45 Levels of all 3 microRNAs depended on platelet numbers in a platelet spike-in experiment but w

46 The deletion of Stat3 increased the platelet numbers in SclCre;V617F;Stat3(fl/fl) mice compa

47 les may have clinical efficacy for improving platelet numbers in thrombocytopenic patients.

48 EGFR1, but not VEGFR2, increases circulating platelet numbers in vivo.

49 The smaller platelet number increase on day 5 after daily dosing ref

50 telet production; its key role in control of platelet number is via generation and stimulation of the

51 a new rupture mechanism, which yields higher platelet numbers, occurs independently of the key regula

52 tivated B cells was reduced in patients with platelet numbers of < 50 x 10(9) cells/L (P = .001), ind

53 ation of 100 micrograms/kg produced a higher platelet number on day 5 than daily administration of 10

54 ficant reduction in neutrophil, monocyte, or platelet numbers or hematocrit levels.

55 ial loads, GPVI-depleted mice showed reduced platelet numbers, platelet activation, and platelet-leuk

56 Variations in platelet number, volume, and function are largely geneti

57 karyocyte, a greater than 3-fold increase in platelet number was consistently observed in c-Myc(-/-)

58 on of 25 or 250 micrograms/kg of PEG-rmMGDF, platelet number was first increased on day 3 and peaked

59 ls and red blood cell, white blood cell, and platelet numbers were also substantially heritable, with

60 Thymic cellularity, blood hematocrit, and platelet numbers were not affected.

61 was accompanied by a 48 to 64% reduction in platelet number, whereas pony 613 did not develop fever